Strong organic growth masks separator execution risk ahead

Delivered ₹493 Cr, actual growth 17.9% YoY

Delivered ₹40 Cr, +79.3% YoY

₹88 Cr ÷ ₹495 Cr = 17.8% (≈18%); OPM 17.4%

Transcript confirms volume high single-digit + value growth; export base was weak YoY prior

Management confirmed near-full utilization, ₹50-60 Cr capex for 30% expansion Jan/Feb 2027

Entry into ₹125 Cr lithium-ion separator via subsidiary. Phase 1 (₹150–200 Cr revenue target), scales to ₹1,100–1,300 Cr long-term. First packaging-adjacent diversification in company's history.

Prior guidance ~₹50–60 Cr for single expansion; now confirmed ₹50–60 Cr for 30% capacity line by Jan 2027, alongside separator ₹30–40 Cr land spend in FY27.

Prior call (FY26) expected 'double-digit domestic growth.' Delivered ₹493 Cr (+17.9% YoY) suggests ahead of modest expectations; volume high single-digit + value growth.

Prior quarter was 'particularly poor'; Q1 FY27 shows 'steady YoY growth' and 'alright' recovery. Base effect, but directional improvement from pessimistic posture.

₹50–60 Cr for ~30% capacity increase. Existing facility near-fully utilized month-to-month; new line operational Jan/Feb 2027.

Years of external research visits, customer meetings. In-house tech development; no external partner. Track record: tobacco cartons → folding → cups → sleeves → flexible → tipping → inks; always best-in-class, never follower. Demanding battery customers will force quality.

Phase 1 targets ₹150–200 Cr topline, good double-digit margins, meets ROCE threshold (>20%). Real upside at scale (500 MSM). Land bought upfront, so Phase 1 asset turn unfair to compare.

Q1 FY26 had forex mark-to-market loss (one-time hit). This quarter more normalized. Not primarily debt-driven.

Target Q4 FY28 (Jan/Feb 2028) commercial production.

Domestic good double-digit, export also positive but lower than domestic. Volume high single-digit, value growth slightly higher. Broad-based across segments.

Phase 1 (70 MSM): ₹150–200 Cr. Phase 2 (500 MSM): ~₹1,100–1,200 Cr, could reach ₹1,200–1,300 Cr depending on pricing.

Primary focus: domestic ACC ecosystem (faster growth than global). Once proven in India, world market opens. Geopolitical factors matter.

Separator qualification timeline faster than anode/cathode. Expect FY28–29 for qualification, testing, initial commercial supply. Patient approach; timeline depends on cell-maker scaling.

No numeric FY27 guidance; historic trend continuing. Environment challenging. For 4–5 years: separator long-term story; packaging major driver for foreseeable future. Precedent: global #1 separator player was packaging co. 10 yrs ago; now separator 20x packaging business.

FY27: ₹100 Cr budget (non-separator). Separator adds ₹30–40 Cr land cost. Total FY27: ₹100–150 Cr. FY28: depends on carton business; may be similar or higher.

No. Developing from various sources + in-house R&D. TCPL product, will be sold as TCPL brand.

Lag of ~1 quarter for price increases to pass through (due to inventory, open orders). EBITDA margin could not hold if not passed through.

Cannot give exact margin now. Expect good double-digit in Phase 1, double-digit ROI. Better return target than existing business, otherwise not sensible.

Mix of volume (higher) and value. Domestic volume growth strong; customer volumes improving. Flexible very strong (hence capex). Export recovering from weak base. Broad-based. Demand sustainable if no new wars; Indian domestic recovery evident.

Plastics always banned on pan masala, nothing new. Notification misleading; structural change in pan masala packaging. TCPL not major supplier; marginal impact short-term.

Government hasn't formalized PLI scheme for battery materials yet; no applications open. Won't speculate on policy not yet live.

Yes, confident; otherwise wouldn't invest. Refer to prior answer on track record.

No one in India manufacturing Li-ion separator or announcing plans. Lead-acid separator makers exist. Globally: China, Korea, Japan dominant (China lead). Multiple fragmented players, no 1–3 company dominance. China >1 TW cell capacity, so separator demand enormous.

Traditional PE flexible packaging lines, not Innofilms. Innofilms tech issues solved; concern now is customer adoption (slower than expected). But product performing well internally/externally. Marketing tool showing sustainability differentiation. FMCG targets 2030 net-zero, but adoption deferred post-COVID.

Room left. Factory-to-factory varies; pan-India operations. Some choked, some capacity. Building expansion room for next year; quick capex decisions within 1.5 quarters if demand spikes.

Operational Jan/Feb 2027. Mix of existing customers (same sector) and new clients targeted; similar packaging type.

Flex is lower-margin business. As flex grows, could drag company margin. But carton also growing, mix healthy. Maintaining good margins last 2 yrs. Expect continuation; unclear if expansion or compression.

Yes, 100% subsidiary. Capex not simple linear scale; Phase 1 is conversion; later phases go backward to base film (more capex). Land bought upfront. Can't multiply by 8x.

Phase 1: lead times similar to packaging machinery. Base film machinery: unknown yet; likely shorter than BOPP. Not seeing 2–3 year lead times expected.

Can't parse detail quarterly; look long-term. No major margin concerns overall.

Cartons at zero duty already. Flexibles helped slightly (duty reduction). Main benefit: sentiment toward India sourcing improving (Europe, UK positive). Flexibles more competitive vs Vietnam/Turkey. More expansion room in exports ahead.

On ₹1,500–2,000 Cr TCPL topline, not a significant drag. Already budgeted in ROCE calculation.

Yes.

Fairly satisfied with ramp. Getting toward 70%-odd number.

Yes, can decide very quickly. Space and infrastructure ready for 2–3 lines; can order machinery tomorrow if needed.

Starting with coating & conversion Q4 FY28. Backward integration pace depends on business ramp-up, demand, machinery availability, cell-maker scaling. How fast cell makers scale is key driver.

Yes. Investing in sustainable business. Real upside at large scale, but Phase 1/2 must deliver returns.

SEMCORP confirmed. Exact capacity tough to quantify, but billions of square meters. China >1 TW cell capacity, so separator requirement enormous. Long way to go for TCPL.

FY27 domestic demand steady, exports alright. Environment uncertain; no formal guidance given due to macro complexity. Management pragmatic vs promotional.

Q1 18% margin maintained despite flex growth (lower-margin segment) and RM cost pass-through lag. Pricing power + operational efficiency offsetting mix drag.

Reaffirmed prior ₹100 Cr packaging capex from FY26 call. Separator land buy-down in FY27; main capex deployment in FY28. Flexible line ₹50–60 Cr included in ₹100 Cr.

No firm FY28 number; pragmatic wait-and-see approach. Separator Phase 1 capex continues through FY28 (targeting Q4 FY28 production).

₹125 Cr investment targeting Q4 FY28 production. In-house technology unproven at scale; customer qualification forecast 1 year (FY28–29). Slippage would delay 500 MSM scale and revenue ramp.

Flex is structurally lower-margin than folding cartons. Growing flex from higher base could compress overall EBITDA %. Management acknowledges this but claims carton also growing, keeping mix healthy. Unproven over cycles.

Exports recovering from 'particularly poor' prior quarter. Management cautious on near-term global outlook. FTA benefits marginal (cartons at zero duty; flexibles get slight duty cut). Competition from Vietnam/Turkey remains.

Strong double-digit domestic growth this quarter, but environment 'challenging' and 'uncertain' per management. If Indian consumption growth stalls or FMCG/pharma capex cycles slow, carton demand could compress.

No competitors in India today for Li-ion separator, but global players (China, Korea, Japan) exist. Lead-acid separator makers may pivot. Government PLI scheme (not yet formalized) could attract new entrants to domestic market.